Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
February 28, 2022 4:02 PM ESTGAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ --
NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHO Additional filings for authorization under review, including in the United States Initiated vaccine shipments globally, with doses administered in the European Union, Australia, Indonesia and South Korea Expanded clinical body of evidence for NVX-CoV2373 across several studies, including: 82.5% overall... More